Observational studies and two randomized controlled trials consistently suggest that, in general, disease recurrence after ...

A significant benefit was observed with Tysabri over Rebif in delaying SPMS disability progression when therapeutic lag was ...

Studies have shown that starting a high-efficacy DMT like Tysabri earlier in the disease course can also lead to less ...

The intervention can match people to newer treatments that are highly effective at reducing MS relapses, including medications like natalizumab, rituximab and ofatumumab. Relapses are when MS ...

Biosimilar natalizumab demonstrated comparable efficacy, safety, and immunogenicity to reference drug Tysabri in patients with relapsing-remitting multiple sclerosis (RRMS), supporting its potential ...

Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer [ID5110] Draft guidance Technology appraisal guidance 24 April ...

It will compete with other biologic therapies for Crohn's, including J&J's IL-12 and IL-23 inhibitor Stelara (ustekinumab), Takeda's Entyvio (vedolizumab) and Biogen's Tysabri (natalizumab ...

and Biogen's multiple sclerosis therapy Tysabri (natalizumab) aren't due to take place until 2023 or 2024. Planned cost-savings now $1.5 billion Novartis, meanwhile, is also in the throes of a ...

Background The ASCEND trial did not find benefit of natalizumab during secondary progressive multiple sclerosis compared with placebo; however, its open-label extension suggests this may be obscured ...

The intervention can match people to newer treatments that are highly effective at reducing MS relapses, including medications like natalizumab, rituximab and ofatumumab. Relapses are when MS ...

Background To compare the effectiveness and treatment persistence of ocrelizumab, cladribine and natalizumab in patients with relapsing–remitting multiple sclerosis switching from fingolimod. Methods ...